COVID-19相关肺血栓形成与血栓栓塞
本文综述COVID-19相关肺血栓形成与血栓栓塞的流行病学、病理生理、诊断和治疗。COVID-19患者即使接受预防性抗凝,肺血栓风险仍显著增高;其机制至少包括高凝状态导致大血管血栓形成和血栓栓塞,以及直接血管和内皮损伤导致原位微血管血栓形成。部分COVID-19肺炎患者低氧血症与肺顺应性损害不成比例,肺血栓形成可解释这一现象。肺栓塞与COVID-19肺炎共享许多体征和症状,诊断具有挑战性。鉴于重症COVID-19的高死亡率和发病率,许多医院系统已实施高于标准VTE预防的积极抗凝方案。
要点
- COVID-19患者即使接受预防性抗凝,肺血栓风险仍显著增高。
- COVID-19血栓倾向由至少两种不同但相互关联的过程驱动:高凝状态导致大血管血栓形成和血栓栓塞,直接血管和内皮损伤导致原位微血管血栓形成。
- 部分COVID-19肺炎患者低氧血症与肺顺应性损害不成比例,肺血栓形成可解释此现象。
- 肺栓塞与COVID-19肺炎共享许多体征和症状,在COVID-19患者中诊断肺栓塞具有挑战性。
- 鉴于重症COVID-19的高死亡率和发病率,许多医院系统已实施高于标准VTE预防的积极抗凝方案。
适用人群与场景
- COVID-19患者,包括接受预防性抗凝者;部分COVID-19肺炎患者出现低氧血症与肺顺应性损害不成比例。
处置流程与药物剂量
- 许多医院系统已实施高于标准VTE预防的积极抗凝方案,用于COVID-19患者。
红旗征与不能漏的情况
- COVID-19患者出现低氧血症与肺顺应性损害不成比例时,肺血栓形成可解释此现象。
研究设计与关键结果
- 综述讨论COVID-19相关肺血栓形成与血栓栓塞的流行病学、病理生理、诊断和治疗。
- COVID-19患者即使接受预防性抗凝,肺血栓风险仍显著增高。
- COVID-19血栓倾向由至少两种不同但相互关联的过程驱动:高凝状态导致大血管血栓形成和血栓栓塞,直接血管和内皮损伤导致原位微血管血栓形成。
证据类型、等级与局限
- 综述。
- 局限:原文未报告局限性。
对床旁实践的改变
- 许多医院系统已实施高于标准VTE预防的积极抗凝方案;本文未给出具体药物、剂量或目标值。
- 肺栓塞与COVID-19肺炎共享许多体征和症状,诊断肺栓塞具有挑战性。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
COVID-19, the disease responsible for the devastating pandemic that began at the end of 2019, has been associated with a significantly increased risk of pulmonary thrombosis, even in patients receiving prophylactic anticoagulation. The predilection for thrombosis in COVID-19 may be driven by at least two distinct, but interrelated, processes: a hypercoagulable state responsible for large-vessel thrombosis and thromboembolism and direct vascular and endothelial injury responsible for in situ microvascular thrombosis. The presence of pulmonary thrombosis may explain why hypoxemia is out of proportion to impairment in lung compliance in some patients with COVID-19 pneumonia. Because pulmonary embolism (PE) and COVID-19 pneumonia share many signs and symptoms, diagnosing PE in patients with COVID-19 can be challenging. Given the high mortality and morbidity associated with severe COVID-19 and the concern that aspects of the disease may be driven by thrombosis, many hospital systems have instituted aggressive anticoagulation protocols above standard VTE prophylaxis. In this review, the epidemiologic and pathophysiologic features, diagnosis, and treatment of COVID-19 pulmonary thrombosis and thromboembolism are discussed.
参考来源
- Poor HD. Pulmonary Thrombosis and Thromboembolism in COVID-19. Chest. 2021. PMID: 34153340. doi:10.1016/j.chest.2021.06.016
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。